Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1
Explore our growing repository of resources designed to provide useful information on inclisiran and other relevant topics for healthcare professionals treating patients with ASCVD.
FREQUENTLY ASKED QUESTIONS
A downloadable guide with answers to key questions you may have about inclisiran.
WHICH OF YOUR PATIENTS ARE ELIGIBLE FOR INCLISIRAN?
The key steps to identify which of your patients could benefit from inclisiran.
INCLISIRAN DOSING AND ADMINISTRATION: ‘HOW TO’ GUIDE
Key steps and important information you need to know about inclisiran dosing and administration on one page.
ORION-10 AND ORION-11 CLINICAL FACT SHEET
A downloadable summary of ORION-10 and ORION-11 trials2 for quick reference and understanding.
INCLISIRAN MOA VIDEO
A video displaying the mechanism of action of inclisiran, the first and only siRNA LDL-C-lowering therapy.1,3,4
ELEVATED LDL-C: THE IMPORTANCE OF EARLY INTERVENTION
A short animation highlighting the consequences of long-term exposure to persistently elevated LDL-C.
Please note that this material should only be shared with patients for whom the decision to prescribe inclisiran has already been made.
This downloadable PDF can be shared with your patients with elevated cholesterol to provide them with further information on their condition and useful information regarding taking Inclisiran.
As the site grows, we will be adding lots of new content. SIGN UP to receive our email communications and make sure you don’t miss the latest updates.
ASCVD, atherosclerotic cardiovascular disease; HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; MOA, mechanism of action; siRNA, small interfering ribonucleic acid.
- Leqvio® Summary of Product Characteristics.
- Ray KK et al. N Engl J Med 2020;382(16):1507–1519.
- Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442.
- Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.